563
Views
347
CrossRef citations to date
0
Altmetric
Research Article

Butyrate Inhibits NF-κB Activation in Lamina Propria Macrophages of Patients with Ulcerative Colitis

Pages 458-466 | Published online: 08 Jul 2009

  • Kirsner JB. Inflammatory bowel disease. Part I: Nature and pathogenesis. Dis Mon 1991;37:605-66.
  • Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerati v e colitis. A long-term followup of 1116 patients. Dig Dis Sci 1993;38:1137-46.
  • Gonzalez-Licea A, Yandley JH. Nature of the tissue reaction in ulcerative colitis. Light and electron microscopic findings. Gastroenterology 1966;51:825-40.
  • Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242(4878):540-6.
  • Cheng Q, Cant CA, Moll T, Hofer-Warbinek R, Wagner E, Birnstiel ML, et al. NK-kappa B subunit-specific regulation of the I kappa B alpha promoter. J Biol Chem 1994;269:13551-7.
  • Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994; 10:405-55.
  • Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996:87:13-20.
  • Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993:187:233-56.
  • Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
  • Beg AA, Finco TS, Nantermet PV, Baldwin AS, Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. MoI Cell Biol 1993;13:3301-10.
  • Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NFkappa Bl precursor protein and the activation of NF-kappa B. Cell 1994:78:773-85.
  • Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signalinduced phosphorylation. Science 1995:267(5203):1485-8.
  • Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 1995:80:573-82.
  • Beutler B, Van Huffel C. An evolutionary and functional approach to the TNF receptor/ligand family. Ann NY Acad Sci 1994:730:118-33.
  • Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992:37:818-26.
  • MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990:81:301-5.
  • Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992:102:529-37.
  • Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mo no nuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993:94:174-81.
  • Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993:104:749-58.
  • Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. MoI Cell Biol 1993:13:6231-40.
  • Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995:86:1243-54.
  • Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 1995:40;949-59.
  • Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994:55:97-179.
  • Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 1992; 176:1583-93.
  • Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-I). J Biol Chem 1992:267:16323-9.
  • Grilli M, Chiu JJ, Lenardo MJ. NF-kappaB and ReI: participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993:143:1-62.
  • Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998:115:357-69.
  • Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998:42:779-87.
  • Jobin C, Herfarth HH, Sartor RB. Dexamethasone inhibits TNFalpha gene expressio n through an I kappa B/NF kappa B pathway in intestinal IEC-6 cells. Gastroenterology 1996;110:A333.
  • Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
  • Conner EM, Brand S, Grisham MB. Inhibition of granulomatous colitis by a selective proteasome inhibitor: antagonists of nuclear transcription factor kappa B activation. Gastroenterology 1996; 110:A887.
  • Bugaut M. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp Biochem Physiol [B] 1987:86:439-72.
  • Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonie mucosa in man. Gut 1980;21:793-8.
  • Roediger WE. The colonie epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980;2(8197):712-5.
  • Roediger WE. The starved colon-diminished mucosal nutrition, diminished absorption, and colitis. Dis Colon Rectum 1990;33: 858-62.
  • Agarwal VP, Schimmel EM. Diversion colitis: a nutritional deficiency syndrome? Nutr Rev 1989;47:257-61.
  • Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christi S, et al. Effect of butyrate enemas on the colonie mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51-6.
  • Senagore AJ, MacKeigan JM, Scheider M, Ebrom JS. Shortchain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992:35:923-7.
  • Vernia P, Marcheggiano A, Caprilli R, Frieri G, Corrao G, Val pian i D, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:309-13.
  • Breuer RI, Buto SK, Christ ML, Bean J, Vernia P, Paoluzi P, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci 1991 ;36: 185-7.
  • Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditi s with butyrate enemas. Am J Gastroenterol 1994;89:179-83.
  • Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995;40:305-7.
  • Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol 1996;91:731-4.
  • Kripke SA, Fox AD, Berman JM, Settle RG, Rombeau JL. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J Parenter Enterai Nutr 1989:13:109-16.
  • Kvietys PR, Granger DN. Effect of volatile fatty acids on blood flow and oxygen uptake by the dog colon. Gastroenterology 1981;80(5pt 1):962-9.
  • Mortensen FV, Nielsen H, Mulvany MJ, Hessov I. Short chain fatty acids dilate isolated human colonie resistance arteries. Gut 1990:31:1391-4.
  • D'Argenio G, Cosenza V, Sorrentini I, De Ritis F, Gatto A, Delle Cave M, et al. Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. Gastroenterology 1994;106:399-404.
  • Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonie epithelial cell line. Gastroenterology 2000; 118:724-34.
  • Segain JP, Raingeard de la Bleuere D, Bourreille A, Leray V, Gervois N, Resales C, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
  • Luhrs H, Gerke T, Schauber J, Dusel G, Melcher R, Scheppach W, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis 2001;16:195-201.
  • Scheppach W. Treatment of distal ulcerative colitis with shortchain fatty acid enemas. A placebo-controlled trial. GermanAustrian SCFA Study Group. Dig Dis Sci 1996;41:2254-9.
  • Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
  • Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989:320:23-8.
  • Den Hond E, Hiele M, Evenepoel P, Peelers M, Ghoos Y, Rutgeerts P. In vivo butyrate metabolism and colonie permeability in extensive ulcerative colitis. Gastroenterology 1998; 115:584-90.
  • Gilbert KM, Weigle WO. Thl cell energy and blockade in GIa phase of the cell cycle. J Immunol 1993;151:1245-54.
  • Siavoshian S, Blottiere HM, Bentouimou N, Cherbut C, Galmiche JP. Butyrate enhances major histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells. Eur J Clin Invest 1996:26:803-10.
  • Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ. n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by shortchain fatty acids. Immunology 1997:92:234-43.
  • Jobin C, Sartor RB. The IkappaB/NF-kappaB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000;278:C451-62.
  • Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and upregulation of IL-10 production. Faseb J 2000:14:2380-2.
  • Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NFkappa B in inflamed mucosa of patients with ulcerative colitis. [In Process Citation]. Am J Gastroenterol 2000:95:3452-7.
  • Scheppach W, Muller JG, Boxberger F, Dusel G, Richter F, Bartram HP, et al. Histological changes in the colonie mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol 1997;9:163-8.
  • Vemia P, Fracasso PL, Casale V, Villotti G, Marcheggiano A, Stigliano V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000:356(9237): 1232-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.